Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIWIT infliximab withdrawal study in rheumatoid arthritis
jRCTs031180001Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by Mitsubishi Tanabe Pharma Corporation. Started May 2016; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs031180001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180001.